Metabolic Plasticity in Melanoma Progression and Response to Oncogene Targeted Therapies

Resistance to therapy continues to be a barrier to curative treatments in melanoma. Recent insights from the clinic and experimental settings have highlighted a range of non-genetic adaptive mechanisms that contribute to therapy resistance and disease relapse, including transcriptional, post-transcr...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Arwa Alkaraki, Grant A. McArthur, Karen E. Sheppard, Lorey K. Smith
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	melanoma metabolism plasticity metastasis targeted therapy resistance Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/1ac67eaffb2a49feb0dabf881ea79789
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:1ac67eaffb2a49feb0dabf881ea79789
record_format	dspace
spelling	oai:doaj.org-article:1ac67eaffb2a49feb0dabf881ea797892021-11-25T17:04:16ZMetabolic Plasticity in Melanoma Progression and Response to Oncogene Targeted Therapies10.3390/cancers132258102072-6694https://doaj.org/article/1ac67eaffb2a49feb0dabf881ea797892021-11-01T00:00:00Zhttps://www.mdpi.com/2072-6694/13/22/5810https://doaj.org/toc/2072-6694Resistance to therapy continues to be a barrier to curative treatments in melanoma. Recent insights from the clinic and experimental settings have highlighted a range of non-genetic adaptive mechanisms that contribute to therapy resistance and disease relapse, including transcriptional, post-transcriptional and metabolic reprogramming. A growing body of evidence highlights the inherent plasticity of melanoma metabolism, evidenced by reversible metabolome alterations and flexibility in fuel usage that occur during metastasis and response to anti-cancer therapies. Here, we discuss how the inherent metabolic plasticity of melanoma cells facilitates both disease progression and acquisition of anti-cancer therapy resistance. In particular, we discuss in detail the different metabolic changes that occur during the three major phases of the targeted therapy response—the early response, drug tolerance and acquired resistance. We also discuss how non-genetic programs, including transcription and translation, control this process. The prevalence and diverse array of these non-genetic resistance mechanisms poses a new challenge to the field that requires innovative strategies to monitor and counteract these adaptive processes in the quest to prevent therapy resistance.Arwa AlkarakiGrant A. McArthurKaren E. SheppardLorey K. SmithMDPI AGarticlemelanomametabolismplasticitymetastasistargeted therapyresistanceNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENCancers, Vol 13, Iss 5810, p 5810 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	melanoma metabolism plasticity metastasis targeted therapy resistance Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	melanoma metabolism plasticity metastasis targeted therapy resistance Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Arwa Alkaraki Grant A. McArthur Karen E. Sheppard Lorey K. Smith Metabolic Plasticity in Melanoma Progression and Response to Oncogene Targeted Therapies
description	Resistance to therapy continues to be a barrier to curative treatments in melanoma. Recent insights from the clinic and experimental settings have highlighted a range of non-genetic adaptive mechanisms that contribute to therapy resistance and disease relapse, including transcriptional, post-transcriptional and metabolic reprogramming. A growing body of evidence highlights the inherent plasticity of melanoma metabolism, evidenced by reversible metabolome alterations and flexibility in fuel usage that occur during metastasis and response to anti-cancer therapies. Here, we discuss how the inherent metabolic plasticity of melanoma cells facilitates both disease progression and acquisition of anti-cancer therapy resistance. In particular, we discuss in detail the different metabolic changes that occur during the three major phases of the targeted therapy response—the early response, drug tolerance and acquired resistance. We also discuss how non-genetic programs, including transcription and translation, control this process. The prevalence and diverse array of these non-genetic resistance mechanisms poses a new challenge to the field that requires innovative strategies to monitor and counteract these adaptive processes in the quest to prevent therapy resistance.
format	article
author	Arwa Alkaraki Grant A. McArthur Karen E. Sheppard Lorey K. Smith
author_facet	Arwa Alkaraki Grant A. McArthur Karen E. Sheppard Lorey K. Smith
author_sort	Arwa Alkaraki
title	Metabolic Plasticity in Melanoma Progression and Response to Oncogene Targeted Therapies
title_short	Metabolic Plasticity in Melanoma Progression and Response to Oncogene Targeted Therapies
title_full	Metabolic Plasticity in Melanoma Progression and Response to Oncogene Targeted Therapies
title_fullStr	Metabolic Plasticity in Melanoma Progression and Response to Oncogene Targeted Therapies
title_full_unstemmed	Metabolic Plasticity in Melanoma Progression and Response to Oncogene Targeted Therapies
title_sort	metabolic plasticity in melanoma progression and response to oncogene targeted therapies
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/1ac67eaffb2a49feb0dabf881ea79789
work_keys_str_mv	AT arwaalkaraki metabolicplasticityinmelanomaprogressionandresponsetooncogenetargetedtherapies AT grantamcarthur metabolicplasticityinmelanomaprogressionandresponsetooncogenetargetedtherapies AT karenesheppard metabolicplasticityinmelanomaprogressionandresponsetooncogenetargetedtherapies AT loreyksmith metabolicplasticityinmelanomaprogressionandresponsetooncogenetargetedtherapies
_version_	1718412761949536256

Metabolic Plasticity in Melanoma Progression and Response to Oncogene Targeted Therapies

Ejemplares similares